Livazo 1mg

Quick links

Choose a section

Quick links to important sections

Advertisements

Livazo 1mg

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Livazo 1mg

Quick Facts

Property Description
Active ingredient Pitavastatin calcium
Form Film-coated oral tablet
Pharmacological class Statin (HMG-CoA Reductase Inhibitor)
General purpose Management of elevated blood lipids
Origin Synthetic compound

Pitavastatin: Defining the Statin Class and Purpose

Livazo 1mg is a prescription-only medication containing the active substance Pitavastatin calcium, which belongs to the widely recognized statin class of drugs. Statins are formally classified as HMG-CoA Reductase Inhibitors. The medication is used for the modification of lipid profiles and the reduction of circulating cholesterol levels. The primary general purpose of this medication is to manage and reduce abnormally elevated concentrations of fats, or lipids, in the bloodstream, thereby functioning as a hypolipidemic agent. This core action is intended for patients needing support to maintain a healthier lipid profile when lifestyle measures alone are insufficient.

Composition, Origin, and Form

The medication is a synthetic compound supplied as a film-coated oral tablet for oral administration. The active ingredient is Pitavastatin calcium, which is a synthetic organic compound. This chemical structure is manufactured specifically for its therapeutic action, differentiating it from certain earlier statins derived from fungal sources. Livazo 1mg is a single-component product where the 1 mg strength denotes the amount of Pitavastatin contained in each individual dose unit, delivered alongside necessary pharmaceutical excipients. Within its class, Pitavastatin is characterized by its high potency and long-lasting action.

General Therapeutic Principle

Pitavastatin works by selectively inhibiting the enzyme HMG-CoA reductase in the liver, which is the rate-limiting step in the body's cholesterol biosynthesis pathway. By blocking this enzyme, the medicine reduces the amount of cholesterol manufactured by the liver. This mechanism of internal production control serves to lower "bad" cholesterol circulating in the blood. Pitavastatin is a potent statin that offers support for managing systemic lipid imbalances, which is a standard approach in preventative cardiovascular care.

Advertisements

What side effects are possible with Livazo 1mg?

Official Safety Profile of Pitavastatin

The safety profile of Pitavastatin (Livazo 1mg) is formally documented in government regulatory sources, classifying adverse reactions by frequency and the body system affected. These classifications structure the understanding of the medicine's risk profile without providing prescriptive advice.


Frequency-Classified Adverse Reactions

Adverse reactions are grouped into categories based on the observed frequency of occurrence:

  • Common: Myalgia (muscle pain), Headache, Constipation, Diarrhea, Nausea, and an increase in hepatic transaminases (a laboratory finding).
  • Uncommon: Dizziness, Insomnia, Fatigue, Pruritus (itching), Rash, and muscle spasms.
  • Rare: Rhabdomyolysis, Hepatitis, Jaundice, Pancreatitis, and Peripheral neuropathy.
  • Very Rare: Interstitial lung disease.

Serious Adverse Reactions and Safety Restrictions

The official labeling highlights specific serious adverse reactions, including rhabdomyolysis and serious hepatobiliary effects such as hepatitis and jaundice. These rare but clinically significant events are documented to provide regulatory context.

The use of Pitavastatin is subject to definitive contraindications as defined in the regulatory documents. These include use in individuals with active liver disease (including unexplained persistent elevated transaminases) and use during pregnancy and lactation.


Population and Exposure Notes

The regulatory profile includes specific safety considerations for certain patient groups, such as those with severe renal impairment and individuals with predisposing factors for myopathy. Furthermore, the risk of muscle-related effects is officially noted as being dose-related, meaning the likelihood increases with higher concentration or exposure.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory information concerning overdosage with Pitavastatin (Livazo 1mg) emphasizes the necessity of immediate emergency action and supportive clinical care. Official labeling states that no specific manifestations of acute, unique overdose are known or formally documented, which focuses treatment on managing potential severe systemic effects.

Immediate Emergency Action and Treatment Focus

In the event of an ingestion that exceeds the prescribed amount, immediate medical attention is required. The official regulatory guidance mandates that patients or caregivers contact a Poison Control Center immediately for the latest expert recommendations on appropriate clinical management. As no specific treatment or antidote is known for Pitavastatin overdosage, treatment must be symptomatic and supportive.

Regulatory Guidance on Management

Management Aspect Official Regulatory Statement
Antidote Availability No specific treatment or antidote is known.
Primary Severe Risk Management targets the known risks of high statin exposure, particularly rhabdomyolysis and potential acute renal failure.
Drug Clearance Due to the high plasma protein binding of Pitavastatin, hemodialysis is unlikely to be of benefit for drug removal.

All care provided following overdosage involves continuous clinical and biological monitoring of the patient's status. The requirement to seek urgent medical help is based on the inherent danger of overexposure to potent medications, which necessitates rapid intervention and observation to mitigate the risk of severe toxicity.

Advertisements

Therapeutic Uses of Livazo 1mg

What Livazo 1mg Treats: Main Uses and Benefits

Livazo (Pitavastatin) is applied across therapeutic domains where additional symptomatic support is needed for long-term cardiovascular risk management and correcting blood fat imbalances (symptoms related to systemic imbalance). The medication is commonly used when sustained lifestyle modifications, such as diet and exercise, are insufficient to achieve necessary lipid targets.


Correcting Imbalances and Reducing Risk

Livazo is used for managing dyslipidemia, which includes conditions like primary hypercholesterolemia and combined (mixed) dyslipidemia. The therapy addresses symptoms related to systemic imbalance and is associated with a reduction of low-density lipoprotein cholesterol (LDL-C) and high triglycerides, while contributing to the supportive therapeutic benefit of helping to increase high-density lipoprotein cholesterol (HDL-C). The therapy supports the patient's long-term management of cardiovascular risk factors and may assist with reducing the likelihood of severe events by playing a role in managing the process of atherosclerosis.


Quick Facts: Therapeutic Support

Property Description
Core Therapeutic Domain Dyslipidemia Management
Primary Symptom Management Reduction of high LDL and triglycerides
Key Patient Benefit Supports management of cardiovascular risk factors
Context of Use When diet and lifestyle alone are insufficient

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility for Livazo (Pitavastatin)

Livazo is strictly contraindicated for use in several specific patient populations, as defined by official regulatory labeling. These prohibitions are non-negotiable and include women who are pregnant or breastfeeding, patients with active liver disease (including acute liver failure or decompensated cirrhosis), and individuals with known hypersensitivity to pitavastatin or any component. Use is also contraindicated with the concurrent administration of cyclosporine.

Restricted and Conditional Use

Population Category Regulatory Status Status Detail
Age Boundary Established/Not Established Approved for adults and for pediatric patients mathbf8 years and older with HeFH; safety in children under 6 years is not established.
Renal Function Conditional Use Patients with moderate to severe renal impairment or on hemodialysis are eligible but subject to a lower maximum daily dosage.
Comorbidity Risk Caution Required Patients with predisposing factors for myopathy, such as uncontrolled hypothyroidism or those aged mathbf65 years and older, require close monitoring.
Acute Conditions Temporary Suspension The medicine must be temporarily withheld in acute, serious conditions that predispose a patient to rhabdomyolysis (e.g., major trauma, sepsis).
Advertisements

What should I know about interactions with other medicines?

The interaction profile for Livazo (Pitavastatin) details required restrictions when co-administering with certain other medicinal products. These constraints are established based on official regulatory documentation regarding pharmacokinetic interactions that increase the systemic exposure of Pitavastatin or pharmacodynamic interactions that raise the documented risk of serious muscle-related events.

Co-administration with Ciclosporin is formally contraindicated. Similarly, the co-administration of Pitavastatin with systemic Fusidic Acid is prohibited, requiring treatment suspension during and for seven days following the completion of the antibiotic therapy.

Interactions that interfere with the hepatic uptake transporter, OATP1B1, lead to specific regulatory dose limitations when co-administered with certain agents:

Interacting Substance Pitavastatin Dose Restriction
Rifampin Dose must not exceed 2 mg once daily.
Erythromycin Dose must not exceed 1 mg once daily.

Caution is required when Pitavastatin is used concurrently with Gemfibrozil (co-administration is generally avoided) or other fibrates, Colchicine, or lipid-modifying doses of Niacin (ge 1 g/ day). These combinations carry a documented additive risk of myopathy and rhabdomyolysis. For administrative context, the medication may be taken with or without food. Caution is also advised for patients who regularly consume excessive quantities of alcohol.

Advertisements

Mechanism of Action

The mechanism of action for Livazo (Pitavastatin) is centered on the competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme responsible for catalyzing the rate-limiting step in endogenous cholesterol synthesis within hepatocytes. By blocking this enzyme, Pitavastatin suppresses the production of mevalonate and reduces intracellular cholesterol concentrations.

This molecular inhibition triggers a compensatory cellular response: the upregulation of Low-Density Lipoprotein (LDL) receptors on the liver cell surface. Increased LDL receptor activity facilitates the enhanced clearance and catabolism of circulating LDL-C and other atherogenic particles from the systemic circulation. This process results in a fundamental reduction of circulating atherogenic lipids.

Beyond lipid control, Pitavastatin exerts pleiotropic effects, which are cholesterol-independent mechanisms. These include the modulation of molecular pathways, such as the Rho/Rac GTPase system, via reduced isoprenoid intermediates. This modulation enhances endothelial function, reduces vascular inflammation, and decreases oxidative stress, contributing to biological stability within the arterial wall.

Advertisements

Dosage and Administration Information

Administration Route and Frequency

Livazo (pitavastatin) 1 mg is a film-coated tablet intended strictly for oral administration and is used as part of a long-term management plan. The medication is taken once daily and can be administered with or without food. Establishing a routine time for the daily dose supports consistent use. The tablet must be swallowed whole and should not be split, crushed, dissolved, or chewed. This medication is used as an adjunct to a cholesterol-lowering diet, which is implemented before starting treatment and maintained throughout its course.


Standard Dosing and Adjustment Patterns

The daily dosage ranges from 1 mg to 4 mg. The prescribed starting dose may vary by region; in some cases, the starting dose is 1 mg once daily, while in others, it is typically 2 mg once daily. The highest permitted daily dose is 4 mg. Adjustments to the dosage (titration) are generally not performed frequently; the dose is reviewed by a specialist at intervals of four weeks or more following analysis of the lipid profile and response to the current dose.


Usage Limitations in Specific Populations

There are specific maximum dosage limits for certain patient groups. For those with moderate to severe renal impairment, the maximum dose is 2 mg once daily. Similarly, for patients with mild to moderate hepatic impairment, the maximum recommended dose does not exceed 2 mg. Conversely, no initial dose adjustment is routinely required for older adults (over 70 years) or for pediatric patients aged 10 years and older up to the 4 mg maximum.

Advertisements

Recent Clinical Evidence

Livazo 1mg: Recent Clinical Evidence

Clinical evidence for pitavastatin (the active substance in Livazo) focuses on its effects on lipid profiles in patients with primary hyperlipidemia or mixed dyslipidemia. Research is conducted to observe changes in cholesterol and triglyceride levels.

Studies on Lipid Profile Modification

Major clinical trials, including long-term observational studies, have investigated the drug's effect on key lipid markers.

Lipid Marker Observation in Clinical Research (Pitavastatin 1–4 mg)
LDL-C (Low-Density Lipoprotein Cholesterol) Studies observed reductions in LDL-C levels, with the 1, mg dose associated with a mean reduction of approximately 32% to 34%.
HDL-C (High-Density Lipoprotein Cholesterol) Research consistently noted an increase in HDL-C levels, which was often sustained over long-term follow-up periods of up to two years.
TG (Triglycerides) Reductions in triglyceride levels were also observed in patient populations with elevated baseline values.

Safety and Tolerability Profiles

Studies evaluate the overall tolerability of the drug. In large post-marketing surveillance trials, the incidence of severe muscle-related side effects, such as myopathy or rhabdomyolysis, was reported to be very low. The most common adverse events recorded in clinical trials often involved mild or moderate musculoskeletal symptoms or gastrointestinal issues. Advanced age (65 years and older) and renal impairment are identified risk factors for muscle symptoms.

Effects on Glucose Metabolism

Some research has explored the drug's impact on glucose markers. Studies suggest that pitavastatin may have a neutral or potentially beneficial profile regarding markers like HbA1c (a measure of average blood sugar), which may be a consideration for patients with, or at risk of developing, type 2 diabetes mellitus. Further analysis is ongoing to fully characterize these long-term effects.

Key Studies & References

  1. Systematic Review on Efficacy, Effectiveness, and Safety of Pitavastatin in Dyslipidemia in Asia
  2. Metaanalysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia
  3. Pitavastatin: an overview of the LIVES study
  4. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes
  5. Annotation of FDA Label for pitavastatin and APOB, LDLR, PCSK9
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Livazo 1mg (FAQ)


Q: Does Livazo 1mg only treat high cholesterol, or does it have other benefits?

A: Official information indicates that besides its main role in reducing cholesterol, the active ingredient pitavastatin also exhibits cholesterol-independent effects. These effects, sometimes called pleiotropic effects, include modulation that may benefit the health of blood vessel linings and help to reduce inflammation in the arteries.


Q: Is it better to take Livazo 1mg in the morning or at night?

A: The medication is taken once daily and may be administered with or without food. Regulatory documents suggest establishing a routine time for the daily dose to promote consistent administration, although the specific time of day is flexible.


Q: Can Livazo 1mg cause trouble sleeping or insomnia?

A: Yes, official safety data lists insomnia (difficulty sleeping) as an uncommon adverse reaction associated with this medication. Any persistent sleep issues after starting treatment are best discussed with a prescribing healthcare professional.


Q: Do I need to have my blood tested regularly while taking Livazo 1mg?

A: Yes, periodic blood testing is necessary. Official regulatory guidance requires that liver function tests be performed before starting treatment and checked periodically thereafter. A specialist also reviews the patient's blood lipid profile at regular intervals to assess the response to the current dose.


Q: Why is Livazo sometimes prescribed for people with diabetes?

A: The active substance pitavastatin is studied for its effect on glucose markers. Studies suggest that pitavastatin may have a neutral or potentially favorable profile regarding blood sugar control indicators like HbA1c, making it a potential consideration for people with, or at risk of developing, type 2 diabetes.


Q: Is it safe to consume alcohol in moderation while taking Livazo 1mg?

A: Official documentation does not specify a restriction on moderate consumption, but notes that caution is advised for patients who regularly consume excessive quantities of alcohol. Excessive alcohol use is a known factor that increases the risk of liver-related adverse events.


Q: What happens if I accidentally take two Livazo 1mg tablets?

A: The official product documentation on overdose states that there is no specific treatment available. If more than the prescribed dose is taken, contact a healthcare professional or emergency service. Management would primarily involve supportive measures.


Q: How long will I likely need to stay on Livazo 1mg for cholesterol management?

A: According to the official prescribing information, Livazo is intended for use as part of a long-term management plan. Treatment is generally maintained indefinitely, alongside the continuation of a cholesterol-lowering diet, to support sustained lipid control.


Q: Are there any specific lifestyle changes needed when starting Livazo 1mg?

A: Yes. The medication is prescribed to be used in combination with a cholesterol-lowering diet. This diet must be implemented before starting the medicine and must be maintained throughout the entire course of treatment.


Q: What should I do if I notice unusual fatigue after starting Livazo 1mg?

A: Fatigue is listed as an uncommon adverse reaction. Any new or unexplained muscle pain, weakness, or fatigue, especially if accompanied by fever or general malaise, should be reported to a prescribing healthcare professional for evaluation.


Q: What is the difference between pitavastatin and Livazo 1mg?

A: Pitavastatin is the name of the active pharmaceutical ingredient contained in the medicine. Livazo is the brand name under which the pitavastatin tablet is sold. The '1 mg' denotes the specific strength of the active ingredient contained in that dose unit.


Q: How long does the effect of one Livazo 1mg tablet last in the body?

A: Livazo is prescribed as a once-daily tablet, which is consistent with its intended use for chronic cholesterol control and its pharmacological profile.


Q: Can Livazo 1mg be used by adolescents or children with high cholesterol?

A: Yes, the medication is approved for use in adults and in pediatric patients aged 8 years and older who have Heterozygous Familial Hypercholesterolemia (HeFH). Safety and effectiveness are not established for children younger than 6 years of age.


Q: Does Livazo 1mg contain any dyes or common allergens?

A: Official labeling confirms that the tablets contain the excipient lactose. Those with known sensitivities, such as galactose intolerance or total lactase deficiency, should consult the complete list of excipients and discuss this with a healthcare professional.


Q: Are there any reported cognitive side effects with Livazo 1mg?

A: As with all statin medicines, there have been rare, post-marketing reports of cognitive impairment following its use, including symptoms like memory loss, forgetfulness, and confusion. These effects are generally not severe and have been reported as reversible upon stopping the medication.


Q: Why is 1mg often the starting dose for Livazo?

A: The 1 mg dose is cited as the official regulatory starting dose in some regions, such as Europe. Doses are tailored to the individual's cholesterol goals, and the final prescribed dosage depends on the patient’s lipid profile.


Q: Does Livazo 1mg affect blood sugar levels in non-diabetic people?

A: Statins, as a class, have been reported to potentially increase blood sugar levels. However, clinical studies focused on pitavastatin specifically suggest that it may have a neutral or possibly favorable profile regarding glucose markers.


Q: Is it safe to drive or operate machinery while taking Livazo 1mg?

A: Official product information notes that the medication has a negligible influence on a person's ability to drive or use machines.


Q: Are there any long-term studies on the safety of Livazo 1mg?

A: Yes, the safety profile of the medication is supported by long-term clinical data. This includes observational studies and post-marketing surveillance trials that have tracked the overall tolerability of the drug over extended periods of use.


Q: What are the signs of a serious, but rare, side effect from Livazo 1mg?

A: Serious, but rare, risks include severe muscle breakdown (rhabdomyolysis) and severe liver issues. Symptoms like new or unexplained muscle pain/weakness, or signs of liver problems (e.g., dark urine, yellowing of skin/eyes) should prompt an immediate call to a healthcare professional or emergency service.


Q: Does Livazo 1mg have a generic version available?

A: Yes, the active ingredient, Pitavastatin calcium, is available under generic labels (e.g., Pitavastatin tablets) in addition to the branded product, Livazo.


Q: Does taking a lower dose like Livazo 1mg still offer significant cholesterol-lowering effects?

A: Clinical studies show that the 1 mg dose provides a significant benefit. This dose is associated with a mean reduction in LDL-C (Low-Density Lipoprotein Cholesterol) levels of approximately 32% to 34%, which is a key measure for managing high cholesterol.


Q: Are there common drug combinations that Livazo 1mg should be used cautiously with?

A: Caution is advised when used alongside certain other medicines. These include fibrates (like Gemfibrozil), Colchicine, and high doses of Niacin (1 gram or more per day). These combinations carry a documented, increased risk of muscle-related issues.

Advertisements

How should Livazo 1mg be stored and disposed of?

How to Store and Dispose of Livazo 1mg

Official regulatory guidelines strictly define the requirements for storing and disposing of Livazo 1mg (pitavastatin) to ensure product stability and environmental safety.

Storage and Handling

The medication must be stored in its original container, tightly closed, and protected from environmental factors. The product must not be stored above 25 C in many regions, and U.S. labeling specifies storage between 20 C and 25 C. To protect the tablets from light and moisture, they must be kept in the outer carton in a dry place. It is mandatory to keep this medicine out of the sight and reach of children using safety caps and secure placement.

Disposal Instructions

Livazo should not be disposed of via household waste, water, or flushing. Official guidance directs users to consult a pharmacist for instruction on how to properly throw away medicines no longer needed. These measures help protect the environment from medicinal residues. Before disposal, identifying information should be scratched off the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Livazo 1mg found in:

A-Z Index: